October 20, 2026
Eli Lilly's Omvoh became the first IL-23 inhibitor to hit its goal in a pivotal pediatric ulcerative colitis study while Nike shares sank 8% on a weak outlook.
What happened
Eli Lilly shares gained 4.8%, adding roughly 59 billion dollars in market value. The jump followed news that its drug Omvoh met the primary endpoint of clinical remission in a one year Phase 3 trial for children with ulcerative colitis. The move was larger than 97% of the company's daily changes over the past three years.
Why it matters
The result creates the first IL-23p19 inhibitor with one year Phase 3 data in this pediatric condition, carving out a first mover advantage in a new patient group. Success broadens Omvoh's label and pushes that revenue stream deeper into protected specialty pharmacy territory, a counterweight to broader consumer health weakness shown by Nike's simultaneous 8% drop on missed revenue.
The case against
The pediatric ulcerative colitis market is small and the Phase 3 success, while statistically significant, reveals nothing yet about how large the commercial uptake will be against entrenched biologic competition. Lilly's overall day looked strong partly because the broader market was split and defensive, not because Omvoh's sales outlook was radically re-rated.
What settles it
The commercial launch numbers for Omvoh in adult ulcerative colitis over the next two quarters, which signal whether the pediatric win actually pulls through demand.